SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible Klebsiella pneumoniae

Microb Drug Resist. 2020 Apr;26(4):334-340. doi: 10.1089/mdr.2019.0079. Epub 2019 Oct 25.

Abstract

This study aimed to determine the mechanism of resistance to piperacillin-tazobactam (TZP) in Klebsiella pneumoniae bloodstream isolates that are susceptible to extended-spectrum cephalosporins (ESCs). Antibiotic susceptibility was determined for K. pneumoniae isolated from children with bacteremia. The β-lactamase genes were detected using a large-scale bla detection method (LARGE-SCALEblaFinder) and confirmed by sequencing analysis. The isolates were further characterized by β-lactamase activity assays and multilocus sequence typing. Among the 300 bloodstream isolates of K. pneumoniae, 11 (3.7%) were TZP resistant but ESC susceptible. The TZP minimum inhibitory concentrations (MICs) of the isolates ranged from 128/4 to >2,048/4 mg/L. Avibactam markedly inhibited piperacillin resistance, reducing the MICs to the range of ≤1 to 8 mg/L. Among the 11 isolates, four hyperproduced SHV-1 and two hyperproduced SHV-11, exhibiting 77- to 496-fold higher β-lactamase activity compared with the SHV-1- and SHV-11-producing reference strains that are susceptible to TZP. OXA-1 was coproduced in three isolates, and the remaining two isolates produced TEM-30. Transformants with recombinant plasmids carrying the β-lactamase genes demonstrated an increase in MICs of TZP. The TZP-resistant and ESC-susceptible isolates were not epidemiologically related. Hyperproduction of SHV-1 and SHV-11 represents a novel mechanism for reducing TZP activity in K. pneumoniae isolates resistant to ESCs. Continuous monitoring and investigation of TZP-resistant isolates are needed in the current era of high TZP consumption.

Keywords: Klebsiella pneumoniae; antimicrobial resistance; beta-Lactamase; piperacillin–tazobactam.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Cephalosporins / pharmacology*
  • Humans
  • Klebsiella Infections / drug therapy
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / metabolism
  • Microbial Sensitivity Tests / methods
  • Piperacillin / pharmacology*
  • Piperacillin, Tazobactam Drug Combination / pharmacology*
  • Tazobactam / pharmacology*
  • beta-Lactamases / metabolism*
  • beta-Lactams / pharmacology

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • beta-Lactams
  • Piperacillin, Tazobactam Drug Combination
  • beta-lactamase PIT-2
  • beta-lactamase SHV-11
  • beta-Lactamases
  • Tazobactam
  • Piperacillin